Additional file 1: of Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer

Figure S1. (A) Synthesis and chemical structure of VERU-111. (B) 1H NMR characterization of VERU-111 using CD2Cl2 as the NMR solvent and full assignment of proton chemical shifts of VERU-111 (EtOAC: ethyl acetate). Spectrum was acquired on a Bruker Advance III 400 MHz NMR spectrometer equipped with a BBO probe at room temperature. (TIF 1059 kb)